Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 16/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 15/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 12/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 11/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.63 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18649967 | 1.00 | HDAC1 (0.63) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL2515782 | 1.00 | HDAC1 (0.63) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL2510571 | 0.87 | HDAC8 (0.68) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL2511481 | 0.87 | HDAC8 (0.68) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL8358218 | 0.85 | HDAC1 (0.46) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL2512622 | 0.77 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL2512620 | 0.77 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL31159482 | 0.77 | HDAC1 (0.92) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL651589 | 0.76 | TUBB4A (0.54) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL2137394 | 0.76 | L3MBTL1 (0.46) | HDAC1HDAC6HDAC8HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552887-B1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | UNIV TAIPEI MEDICAL (TW) | 2018-10-24 | — | — | EP | claimed |
| EP-2552887-B1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | UNIV TAIPEI MEDICAL (TW) | 2018-10-24 | — | — | EP | disclosed |
| US-9598364-B2 | Indolyl or indolinyl hydroxamate compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2017-03-21 | — | — | US | disclosed |
| US-20140364477-A1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2014-12-11 | — | — | US | disclosed |
| US-8846748-B2 | Indolyl or indolinyl hydroxamate compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2014-09-30 | — | — | US | disclosed |
| EP-2552887-A2 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | Taipei Medical University (TW) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011126821-A2 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-10-13 | — | — | WO | disclosed |
| US-20110245315-A1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245315-A1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | IDH3A, IDH2, IDH3B | HDAC1 8/4885HDAC6 35/4885HDAC8 128/4885 |
| US-20140364477-A1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | IDH3A, IDH2, IDH3B | HDAC1 8/4885HDAC6 35/4885HDAC8 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.